Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2010. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification rather than a financial performance report.
Material Changes
The filing details the company's issued share capital as of February 26, 2010:
- Total issued Ordinary shares: 5,665,676,135 (25p each).
- Treasury shares held: 474,194,158.
- Total voting rights: 5,191,481,977.
No material changes to financial performance or operational status are reported in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. Its sole purpose is to provide the denominator for shareholder calculations regarding notification requirements under the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total voting rights count of 5,191,481,977 for compliance calculations.
- Confirm the number of treasury shares (474,194,158) held as of February 26, 2010.
- Note that this filing does not contain financial results; refer to Form 20-F for financial data.